CClinicalTrials.gg
Status unknownNCT05412355Updated Jun 24, 2022

Effects of Incomplete ERAS on Clinical Outcomes in Patients With Colorectal Cancer

An observational study in Colorectal Neoplasms and Enhanced Recovery After Surgery, sponsored by Wuhan Union Hospital, China. Status unknown at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-24.

Sponsored by Wuhan Union Hospital, China · Observational

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

Enhanced recovery after surgery (ERAS) has been reported to be associated with improved outcomes in many studies, most of which involve short-term effects. Only a few studies have reported the long-term effects of highly compliant ERAS. However, to the best of our knowledge, there are no large-scale comparisons between incomplete ERAS (compliance \< 70%) and non-ERAS. The aim of this comparative study is to analyze and evaluate the long-term outcomes of incomplete ERAS in laparoscopic colorectal cancer surgery.

02

Conditions studied

  • Colorectal Neoplasms
  • Enhanced Recovery After Surgery
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 250 across 1,226 observational studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Wuhan Union Hospital, China is the lead sponsor of 230 studies on the registry; 104 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

In this study, we are going to collect clinical data of patients undergoing laparoscopic radical surgery from four large hospitals between August 2008 and December 2016.

Inclusion criteria

    1. age older than 18 years;2. pathological diagnosis of colorectal cancer;3. radical surgery was performed; and 4. laparoscopic surgery was performed.

Exclusion criteria

Exclusion Criteria:

    1. ERAS compliance ≥70%; 2. open surgery; 3. switch to laparotomy after laparoscopic surgery; 4. pregnancy or lactation; 5. severe mental illness; 6. Simultaneous malignant tumors of multiple organs; 7. History of other malignant tumors; and 8. Emergency radical colorectal resection due to obstruction, perforation or bleeding.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Incomplete ERAS

    Incomplete ERAS was defined as ERAS compliance \< 70%.

    Procedure: ERAS protocol

  • Non-ERAS

    non-ERAS was defined as not executing any ERAS programs.

    Procedure: ERAS protocol

Interventions

  • ProcedureERAS protocol

    ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.

06

What researchers measure

Primary outcomes

  1. long-term survival

    5-year Disease free survival and overall survival

    Time frame: Each patient will be followed for 5 years or until death

Secondary outcomes

  1. Postoperative complications

    Postoperative complications within 30 days after surgery.

    Time frame: within 30 days after surgery

07

Study locations

1 of 2 sites recruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
    Wuhan, Hubei 430000, China
    Recruiting
  • Union Hospital,Tongji Medical College, Huazhong University of Science and Technology.
    Wuhan, Hubei 430000, China
    Active, not recruiting
08

References and documents

Individual participant data

Plan to share: Yes — After the funders finished the study,the data will be available,if approved by PI.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05412355
Lead sponsor
Wuhan Union Hospital, China
Responsible party
Xiaogang Shu (Prof., Wuhan Union Hospital, China) — Principal investigator
First posted
Jun 9, 2022
Start date
Jun 1, 2022
Primary completion
Aug 10, 2022 (estimated)
Completion
Oct 10, 2022 (estimated)
Last update
Jun 24, 2022

Study contacts

Chenxing Jian, MD.
Contact
ptyyjcx@126.com
86-13959538950
Xiaogang Shu, MD.,PHD.
principal investigator · Wuhan Union Hospital, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion